New Breast Cancer
Treatment Tykerb Pill Competes Against Herceptin - GlazoSmithKline GSK
Product Passes Blood Brain Barrier - Low Heart Risk
June 4th 2006
Tykerb, a new drug produced by GlazoSmithKline (GSK), is showing promise
in treating breast cancer where Herceptin fails to respond. Tykerb is a
pill that can be taken orally, compared to other chemotherapy drugs
which must be injection. It is also a smaller molecule and can pass
through the blood brain barrier to attack breast cancer that has spread
to the brain.
According to the researchers, 62 percent of women with HER2 IBC cancers
had a clinical response to Tykerb. The women in the study had aggressive
HER2 type of breast cancer, and had already taken other drugs until they
failed to respond to treatment. These other drugs included Roche
Holding AG's and Genentech Inc's top-selling Herceptin.
The study found that the progression time for women taking Tykerb in
combination with a chemotherapy drug of 36.9 weeks, compared to 19.7
weeks for those taking chemotherapy agent capecitabine alone. Tykerb
nearly doubled the progression time.